Sulindac-Derived RXR伪 Modulators Inhibit Cancer Cell Growth by Binding to a Novel Site
详细信息 查看全文
- 作者：Liqun Chen1 ; 2 ; 4 ; Zhi-Gang Wang3 ; 4 ; Alexander E. Aleshin2 ; 4 ; Fan Chen1 ; 2 ; Jiebo Chen1 ; 2 ; Fuquan Jiang1 ; Gulimiran Alitongbieke1 ; Zhiping Zeng1 ; Yue Ma1 ; Mingfeng Huang1 ; Hu Zhou1 ; 2 ; Gregory Cadwell2 ; Jian-Feng Zheng3 ; Pei-Qiang Huang3 ; Robert C. Liddington2 ; Xiao-kun Zhang1 ; 2 ; xzhang@sanfordburnham.org" class="auth_mail ; Ying Su1 ; 2 ; ysu@sanfordburnham.org" class="auth_mail
- 刊名：Chemistry & Biology
- 出版年：22 May 2014
- 年：2014
- 卷：21
- 期：5
- 页码：596-607
- 全文大小：2972 K
文摘
- •
Two sulindac analogs with improved RXR伪-dependent anticancer efficacy are reported
- •
The sulindac analogs regulate tRXR伪 activity by a unique binding mechanism
- •
The sulindac analogs bind to a tetramer of RXR伪 ligand-binding domain
- •
Crystal structures reveal a unique small molecule binding site of RXR伪